LAKE FOREST, CALIFORNIA, UNITED STATES — February 17, 2026 STAAR Surgical announced that the U.S. Food and Drug Administration has approved an expanded age indication for its implantable vision correction device EVO ICL, extending eligibility to patients aged 21 to 60 years. The regulatory decision follows publication of long-term clinical safety data supporting the device’s performance and durability. The expanded label is expected to make lens-based refractive correction accessible to millions of additional patients while reinforcing a broader market shift away from corneal tissue-removing laser procedures.
Science Significance
EVO ICL (Implantable Collamer Lens) represents a lens-based refractive correction technology designed to treat moderate to severe myopia and myopic astigmatism. Implanted behind the iris and in front of the natural crystalline lens, the biocompatible device corrects vision without removing corneal tissue. This structural preservation enables reversible vision correction while maintaining the eye’s natural anatomy and optical integrity. Clinical trial data tracking 629 eyes over three years demonstrated a strong safety index, minimal adverse events, and extremely low cataract incidence, reinforcing the scientific reliability of phakic intraocular lens platforms in refractive surgery evolution.
Regulatory Significance
The FDA’s expansion of the approved age range from 21–45 to 21–60 years reflects confidence in long-term clinical performance and post-implant safety outcomes. Regulatory review incorporated trial evidence, global clinical experience, and published literature evaluating device tolerability across broader patient populations. As a Class III implantable ophthalmic device, EVO ICL is subject to stringent premarket approval standards, including biocompatibility, surgical safety, and visual acuity performance. Label expansion signals regulatory validation of both safety durability and procedural reproducibility in older refractive populations.
Business Significance
Advertisement
The expanded indication significantly increases the addressable U.S. refractive surgery market. Nearly eight million additional adults now fall within the eligible age range, strengthening long-term commercial growth potential. Market analytics indicate a broader procedural shift, with lens-based correction increasingly preferred among patients with high myopia. Implant adoption growth, combined with declining laser procedure volumes, positions EVO ICL as a major revenue driver within STAAR Surgical’s ophthalmic device portfolio. Indication expansion not only increases patient eligibility but reinforces competitive positioning within the global refractive technology landscape.
Patients’ Significance
For patients, the regulatory expansion enhances access to an alternative vision correction pathway that preserves corneal structure and offers long-term flexibility. The procedure is minimally invasive and reversible, allowing future treatment options if vision needs evolve. Individuals aged 46–60 — previously ineligible in the U.S. — may now benefit from improved distance vision without reliance on glasses or contact lenses. Broader eligibility supports personalized refractive care, particularly for patients unsuitable for laser procedures due to corneal thickness or high refractive error.
Policy Significance
The FDA decision reflects broader healthcare system recognition of implantable ophthalmic technologies as viable long-term vision correction solutions. As refractive care demand grows alongside aging populations, regulatory frameworks are evolving to support safe adoption of advanced intraocular implants. Expanded indications also align with healthcare access priorities by enabling more patients to benefit from clinically validated surgical innovations. Policy momentum toward device innovation, evidence-based labeling, and surgical technology adoption continues to shape ophthalmic care delivery models.
The FDA’s approval of an expanded age indication for EVO ICL marks a pivotal advancement in refractive surgery evolution. By validating long-term safety while broadening patient eligibility, regulators have reinforced the growing role of implantable lens technologies in vision correction. As market dynamics shift away from laser-based procedures, EVO ICL stands positioned to redefine refractive treatment pathways through anatomically preserving, patient-centric surgical innovation.
Source: STAAR Surgical press release
